GLP-1 stimulates the -cells to produce Insulin, blocks pancreatic -cells' glucagon release via somatostatin (96), slows down gastric emptying (131), improves peripheral glucose tolerance (132), suppresses appetite in the hypothalamus and amygdala (97), increases -cell mass, GSIS, and elicits protection from glucolipotoxicity (133) and apoptosis (134)
Why Zepbound Works Better Than Single GLP-1s Zepbounds dual-agonist approach may lead to greater weight loss compared to single-agonist medications
For example, Eli Lilly has just reported clinical trial results showing the benefits of its GLP-1, Zepbound (tirzepatide), in reducing the occurrence of sleep apnea events among people with obesity or overweight
Miller, Women's Health , 9/18
GLP1-S improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity
The standard BMI categories were developed primarily from European population data, and they do not apply equally across all ethnic groups